Startup Funding News
Explore funding rounds, the companies behind them and the investors taking part.
- Rounds
- 479 All time
- Disclosed funding
- $19.6B 405 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| CM CREATE MedicinesCompany profile Develops in vivo immune programming platform for scalable, repeat-dose immunotherapies Develops in vivo immune programming platform for scalable, repeat-dose immunotherapies | $122M | Series B | Biotech | United States | Investors | |
| DT Degron TherapeuticsCompany profile Develops molecular glue degrader medicines targeting previously undruggable proteins Develops molecular glue degrader medicines targeting previously undruggable proteins | $40M | Series A+Series A | Biotech | China | Investors | |
| AG Avant GenomicsCompany profile Automates liquid biopsy sample preparation for consistent, scalable cancer DNA extraction Automates liquid biopsy sample preparation for consistent, scalable cancer DNA extraction | >$3M | Seed | Biotech | United States | Investors | |
| Q QuartzBioCompany profile Provides AI-powered sample and biomarker intelligence platform for clinical-stage biopharma Provides AI-powered sample and biomarker intelligence platform for clinical-stage biopharma | Undisclosed | Growth | Biotech, Healthtech | United States | Investors | |
| U UroMemsCompany profile Develops innovative, implantable mechatronics technology to treat stress urinary incontinence Develops innovative, implantable mechatronics technology to treat stress urinary incontinence | $60M | StrategicUndisclosed | Biotech, Healthtech | France | Investors | |
| AB Autoimmunity BioSolutionsCompany profile Genetically guided therapies targeting elevated soluble IL7 receptor levels in autoimmune disease. Genetically guided therapies targeting elevated soluble IL7 receptor levels in autoimmune disease. | $1M | Seed extensionSeed | Biotech | United States | Investors | |
| TB Tolemy BioCompany profile Develops AI-enabled platform for cell biology research to help biopharma teams interpret and optimise experimental workflows Develops AI-enabled platform for cell biology research to help biopharma teams interpret and optimise experimental workflows | €1.4M | Pre-SeedPre-seed | Biotech | United Kingdom | Investors | |
| IL Isomorphic LabsCompany profile Builds an AI-first drug design engine to accelerate discovery and development across multiple therapeutic areas Builds an AI-first drug design engine to accelerate discovery and development across multiple therapeutic areas | $2.1B | Series B | Biotech | United Kingdom | Investors | |
| A AlgorithmiqCompany profile Algorithmiq develops quantum algorithms and software for research in chemistry, materials and life sciences. Algorithmiq develops quantum algorithms and software for research in chemistry, materials and life sciences. | €18M | Series B | Biotech, Developer tools | Italy | Investors | |
| N Develops nanostructured sensor chips for rapid pathogen detection in food | €2.6M | Seed | Biotech | Germany | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.
Browse rounds by topic
Geography
Featured selections
Nordic Foodtech Fund II pairs early capital with scientific expertise
An EIF pledge of up to €30m supports a fund targeting €80m for science-led agrifood companies.
Read the research →